Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis.
- Published In:
- International immunopharmacology, 118, 109953 (2023)
- Authors:
- Sosne, Gabriel(2), Berger, Elizabeth A(2)
- Database ID:
- RPEP-07408
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07408APA
Sosne, Gabriel; Berger, Elizabeth A. (2023). Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis.. International immunopharmacology, 118, 109953. https://doi.org/10.1016/j.intimp.2023.109953
MLA
Sosne, Gabriel, et al. "Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis.." International immunopharmacology, 2023. https://doi.org/10.1016/j.intimp.2023.109953
RethinkPeptides
RethinkPeptides Research Database. "Thymosin beta 4: A potential novel adjunct treatment for bac..." RPEP-07408. Retrieved from https://rethinkpeptides.com/research/sosne-2023-thymosin-beta-4-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.